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Abstract
The compounds 1-(2,6-diethylphenyl)imidazolidine-2-thione and 2-(2,6-diethylphenyl)imidazolidine showed the almost same activity as
octopamine in stimulating adenylate cyclase of cockroach thoracic nervous system among 70 octopamine agonists, suggesting that only
these compounds are full octopamine agonists and other compounds are partial octopamine agonists. The quantitative structure-activity
relationship of a set of 22 octopamine agonists against receptor 2 in cockroach nervous tissue, was analyzed using receptor surface
modeling. Three-dimensional energetics descriptors were calculated from receptor surface model/ligand interaction and these three-
dimensional descriptors were used in quantitative structure-activity relationship analysis. A receptor surface model was generated using
some subset of the most active structures and the results provided useful information in the characterization and differentiation of
octopaminergic receptor.












EGTA ethylene glycol bis(β-aminoethyl ether)-N,N,N’,N’-tetraacetic acid
GFA genetic function approximation
G/PLS genetic partial least squares
IND 2-aminomethyl-2-indanol
LAH lithium aluminum hydride
MCSG maximum common subgroup
MCT6 2-(2-methyl-4-chlorophenylimino)thiazine
OA octopamine
PLS partial least squares
QSAR quantitative structure-activity relationship
SBAT 2-(substituted benzylamino)-2-thiazoline
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has been found to be present in high concentrations in various insect
tissues, is the monohydroxyllic analogue of the vertebrate hormone
noradrenalin. Octopamine was first discovered in the salivary glands
of the octopus by Erspamer and Boretti (1951). It has been found
that octopamine is present at a high concentrations in various
invertebrate tissues (Axelrod and Saavedra, 1977). This
multifunctional and naturally occurring biogenic amine has been
well studied and established as 1) a neurotransmitter, controlling
the firefly light organ and endocrine gland activity in other insects;
2) a neurohormone, inducing mobilization of lipids and
carbohydrates; 3) a neuromodulator, acting peripherally on muscles,
fat body, corpora cardiaca and the corpora allata, and 4) a centrally
acting neuromodulator, influencing motor patterns, habituation and
even memory in various invertebrate species (Evans, 1985, 1993).
The action of octopamine is mediated through various receptor
classes. Three different receptor classes OAR1, OAR2A and OAR2B
have been distinguished from non-neuronal tissues (Evans, 1981).
OAR2 is coupled to G-proteins and is specifically linked to an
adenylate cyclase. Thus, the physiological actions of OAR2 have
been shown to be associated with elevated levels of cAMP
(Nathanson, 1985). In the nervous system of the locust, Locusta
migratoria, a particular receptor class was characterized and
established as a new class OAR3 by pharmacological investigations
of the [3H]OA binding site using various agonists and antagonists
(Roeder, 1990, 1992, 1995; Roeder and Gewecke, 1990; Roeder
and Nathanson, 1993).
Recently much attention has been directed at the octopamine
agonist as a valid target in the development of safer and selective
pesticides (Jennings et al., 1988; Hirashima et al., 1992; Ismail et
al., 1996). Structure-activity studies of various types of octopamine
agonists and antagonists were also reported using the nervous tissue
of the migratory locust, L. migratoria (Roeder, 1990, 1992, 1995;
Roeder and Gewecke, 1990; Roeder and Nathanson, 1993).
However, information on the structural requirements of these
octopamine agonists and antagonists for high octopamine-receptor
ligands is still limited. It is therefore of critical importance to provide
information on the pharmacological properties of octopamine
receptor types and subtypes. Our interest in octopaminergic agonists
was aroused by the results of quantitative structure-activity
relationship (QSAR) studies using various physicochemical
parameters as descriptors (Hirashima et al., 1999a; Pan et al., 1997a)
and receptor surface modeling (Hirashima et al., 1998a).
Furthermore, molecular modeling and conformational analyses were
performed in Catalyst/Hypo to gain a better understanding of the
interactions between octopaminergic antagonists and OAR3 in order
to determine the conformations required for binding activity (Pan et
al., 1997b). A similar procedure was repeated using octopamine
agonists (Hirashima et al., 1999b). However, binding activity is not
enough for evaluating octopamine-agonist activity, because it is
difficult to determine the different activities of octopamine agonists
and antagonists. In drug discovery, it is common to have measured
activity data for a set of compounds acting upon a particular protein
but not to have knowledge of the three-dimensional structure of the
protein active site. In the absence of such three-dimensional
information, one can attempt to build a hypothetical model of the
receptor site that can provide insight about receptor site
characteristics. Such a model is known as a receptor surface model,
which provides compact and quantitative descriptors that capture
three-dimensional information about a putative receptor site. Thus,
the current work is aimed to perform 3D receptor surface modeling
on a set of octopamine agonists using the thoracic nervous system
of the American cockroach, Periplaneta americana, in which
octopamine-agonist action is thought to be due to cAMP elevation
at OAR2 (Hirashima et al., 1992).
Materials and Methods
Synthesis of OA agonists
AEAs 1-7, IND 39 and THI 40 were synthesized from
trimethylsilyl cyanide and the corresponding aldehyde in the
presence of catalytic amount of anhydrous zinc iodide, followed by
reduction with LAH (Hirashima et al., 1990). AEAs 23 and 24 were
obtained by reducing optically active mandelic amides, which was
obtained from optically active manelic acids via their esters, with
LAH (Wu et al., 1989). AITs 9-11, 41-43, MCT6 44, DET5 45, DET6
46, SBATs 12-14, 47-57, APATs 58-59 and BPAT 60 were
synthesized by cyclization of the corresponding thiourea with conc.
hydrogen chloride (Hirashima et al., 1994). AIOs 15-16, 61-65, CAO
17 and DCAO 66 were obtained by cyclodesulfurizing the
corresponding thiourea with yellow mercuric oxide (Hirashima et
al., 1996). SPITs 18 and 67-70 were synthesized by the cyclization
of monoethanolamine hydrogen sulfate with arylisothiocyanate in
the presence of sodium hydroxide as described in the previous report
(Hirashima et al., 1998b). AIIs 19-22 were prepared according to a
reported method by refluxing the corresponding substituted aniline
and 1-acetyl-2-imidazolidone in phosphoryl chloride followed by
hydrolysis (Nathanson and Kaugars, 1989). The structures of the
compounds were confirmed by 1H and 13C NMR measured with a
JEOL JNM-EX400 spectrometer at 400 MHz, TMS being used as
an internal standard for 1H NMR and elemental analytical data.
Chemicals
Octopamine, theophylline (1,3-dimethylxanthine), tyramine
41 and EGTA were purchased from Nacalai Tesque,
www.nacalai.co.jp/en/; GTP and DL-synephrine 8 was from Sigma
Chemical Co., www.sigmaaldrich.com; ATP disodium salt was from
Kohjin Co., www.kohjin.co.jp/english/; LAH was from Chemetall
GmbH, www.chemetall.com. The cAMP radioimmunoassay kit (cord
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Insect culture
Males and females of Periplaneta americana were used
indiscriminately, as their nervous systems exhibited no gross
structural or neurochemical differences. The insects were reared
under crowded conditions in this laboratory at 28 oC with a
photoperiod of 12 h light:12 h dark and at a relative humidity of 65-
70% for more than 7 years. They were provided with an artificial
mouse diet (Oriental Yeast Co., Chiba, Japan, www.oyc.co.jp/e/)
and water ad libitum.
Adenylate-cyclase assay
The adenylate-cyclase assay was conducted on adult P.
americana as described previously (Hirashima et al., 1992, 1994,
1996, 1998b). Thoracic nerve cords of P. americana were
homogenized (15 mg/ml) in a 6 mM Tris-maleate buffer (pH 7.4)
using a chilled microtube homogenizer (S-203, Ikeda Sci., Tokyo,
Japan,  www.biorobotics.com/Pages/ikeda.html) as described
previously. The homogenate was diluted (1 mg/ml) in 6 mM Tris-
maleate, centrifuged at 120,000 g at 4 oC for 20 min. The supernatant
was discarded, the pellet was resuspended by homogenizing (1 mg/
ml) in the buffer, and again centrifuged at 120,000 g at 4 oC for 20
min. The resulting pellet (P2) resuspended in the buffer was
equivalent to the starting amount (15 mg/ml). The adenylate-cyclase
activity was measured according to Nathanson’s procedure under
optimal conditions (Hirashima et al., 1992, 1994, 1996, 1998b) in a
test tube containing 200 µl of 120 mM Tris-maleate (pH 7.4,
including 15 mM theophylline, 12 mM MgCl2 and 0.75 mM EGTA),
60 µl of the P2 fraction and 30 µl of each synthesized compound
solution in polyethylene glycol. An appropriate solvent control was
run in parallel. The enzyme reaction (5 min at 30oC) was initiated
by adding 10 µl of a mixture of 3 mM GTP and 60 mM ATP, stopped
by heating at 90 oC for 2 min and then centrifuged at 1000 g for 15
min to remove the insoluble material. The cAMP level in the
supernatant was measured using a radioimmunoassay (Hirashima
et al., 1992, 1994, 1996, 1998b). Protein concentration was
determined by the Lowry method (Lowry et al., 1951), using bovine
serum albumin (Sigma) as the standard. Enzyme activity in each
assay was corrected using octopamine as a reference. The Vmax
values (mostly at 0.1 mM) were calculated relative to octopamine
(100%) and control (0%).
Computational details
Molecular alignment: All experiments were conducted with
Cerius2 3.8 QSAR environment from Accelrys, www.accelrys.com,
on a Silicon Graphics O2, runnning under the IRIX 6.5 operating
system. Multiple conformations of each molecule were generated
using the Boltzmann Jump as a conformational search method. The
upper limit of the number of conformations per molecule was 150.
Each conformer was subjected to an energy minimization procedure
to generate the lowest energy conformation for each structure.
Alignment of structures through pair-wise superpositioning placed
all structures in the study compounds in the same frame of reference
as the shape reference compounds, which were selected as a
conformer of the most active octopamine agonists. The method used
for performing the alignment was MCSG. This method looks at
molecules as points and lines, and uses the techniques of graph theory
to identify patterns. It finds the largest subset of atoms in the shape
reference compound that is shared by all the structures in the study
table and uses this subset for alignment. A rigid fit of atom pairings
was performed to superimpose each structure so that it overlays the
shape reference compound.
Receptor surface modeling: Receptor surface models are
predictive and sufficiently reliable to guide the chemist in the design
of novel compounds. These descriptors are used for predictive QSAR
(quantitative structure-activity relationship) models. This approach
is effective for the analysis of data sets where activity information
is available but the structure of the receptor site is unknown. Receptor
surface modeling attempts to postulate and represent the essential
features of a receptor site from the aligned common features of the
molecules that bind to it. This method generates multiple models
that can be checked easily for validity. Once a reasonable receptor
surface model has been defined, a series of structures can be
evaluated against the model. When a receptor model has been
generated and the models have been aligned, a QSAR can be built
using data from the receptor-structure interactions. The results of
the minimization procedure were used as descriptors either to refine
the model or to predict activity. Three-dimensional energetics
descriptors were calculated from receptor surface model/ligand
interaction. These three-dimensional descriptors were used in QSAR
analysis.
A receptor surface model represents the global volume that
can accommodate one or more molecules and can be seen as the
shape of an active site built from the ligands that fit into it in their
“active” conformation. The descriptors used in this study account
for phenomena that occur at the contact surface between the ligands
and the protein active site. A receptor surface model represents
essential information about the hypothetical receptor site as a three-
dimensional surface with associated properties mapped onto the
surface model. The location and shape of the surface represent
information about the steric nature of the receptor site: the associated
properties represent other information of interest, such as
hydrophobicity, partial charge, electrostatic potential and hydrogen-
bonding propensity. The isosurface procedure produces a surface
that entirely encloses the molecules over which it is generated. The
surface has no holes and is known as a closed model. Receptor
surface models are best constructed from a set of the most active
analogues that are chosen to cover the variety of steric and
electrostatic variations likely to appear in the test data. The approach
we took was to automatically build a set of different receptor surface
models from different combinations of the most active analogues,
and then use a variable-selection technique such as G/PLS to
discover the receptor surface model whose descriptors yield the best
QSARs of the full training set. G/PLS allows the discovery and use
of nonlinear descriptors by using spline-based terms.
Genetic partial least squares: Due to the large number of
points used as independent variables, genetic partial least squares
(G/PLS) was used to derive the QSAR models. G/PLS, a variation
of genetic function approximation (GFA), can be run as an alternative
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features of two methods: GFA and partial least squares (PLS). Both
GFA and PLS have been shown to be valuable analysis tools in
cases where the data set has more descriptors than samples. In PLS,
variables might be overlooked during interpretation or in designing
the next experiment even though cumulatively they are very
important. This phenomenon is known as “loading spread”. In GFA,
equation models have a randomly chosen proper subset of the
independent variables. As a result of multiple linear regression on
each model, the best ones become the next generation and two of
them produce an offspring. This was repeated 10000 (default 5000)
times. For other settings, all defaults were used. Loading spread
does not occur because at most one of a set of co-linear variables is
retained in each model. G/PLS combines the best features of GFA
and PLS (Cerius2 tutorial. Accelrys Inc., www.accelrys.com/
cerius2). G/PLS retains the ease of interpretation of GFA by back-
transforming the PLS components to the original variables.
Results
A set of 22 molecules, shown in Table 1, whose stimulatory
activities of adenylate cyclase were tested using the receptor surface
model in the cockroach central nervous tissue, and whose Vmax
values were 40% or larger than 40%, were selected as the target
training set. The molecular structures and experimental biological
activities are listed in Fig. 1a and Table 1, respectively. Vmax means
the maximal response relative to octopamine and was expressed as
the mean of 4 independent expreriments. Values of pKa (log of the
reciprocal of Ka) were used as octopamine-agonist activity index.
Ka is the concentration of octopamine agonist necessary for half-
maximal activation of adenylate cyclase.  The Ka values were
calculated from at least 5 concentrations ranging from 10-7 M to 10-3
M using a Macintosh personal computer system, and a sigmoidal
curve-fitting program designed for log dose-probit activity analyses.
2-(2,6-Diethylphenylimino)imidazolidine 21 showed the highest
activity followed by CAO 17, OA 5 and 1-(2,6-
diethylphenyl)imidazolidine-2-thione 18 in study compounds. The
compounds 18 and 21 showed the almost same Vmax as octopamine,
suggesting that only these compounds are full octopamine agonists
and other compounds are partial octopamine agonists.
A receptor surface model was generated (Figs. 2 and 3)
Figure 1. Structures of octopamine agonists used for regression analysis in
study (a) and test (b) sets.
Table 1. Effect of OA agonists on the adenylate-cyclase activity in homogenates
of American cockroach nerve cords in study seta
aSee the text for experimental details.  The adenylate-cyclase activity of P.
americana was measured according to Nathanson’s procedure and the cAMP
levels were measured by a RIA.  Basal (control) and OA (100 µM)-stimulated
(Vmax) adenylate cyclase activities were 116.2+5.4 and 1,473.3+59.3 pmol
cAMP/min/mg of protein, respectively.  In parentheses, 95% confidence limits
are shown.  Ka and 95% confidence limit values were calculated with the
Macintosh personal computer system using a sigmoidal curve-fitting  program
designed for log dose-probit activity analyses.
bCalculated by Equation (1).
cIn case predicted activity is overestimated, deviation is obtained by calculating
predicted activity subtracted by experimental value and indicated by minus. In
case predicted activity is underestimated, deviation is obtained by calculating
experimental activity subtracted by predicted value.
Compound pKa




1 2-MeO 45.8r3.2 1506.37(1218.42-1871.21) 2.82 2.84 -0.02
2 4-Br 45.2±2.7 93.35(84.46-103.29) 4.03 4.1 -0.07
3 4-Cl 72.1±1.2 68.77(62.72-75.51) 4.16 3.93 0.23
4 4-F 44.0±0.9 273.39(252.31-296.76) 3.56 3.69 -0.13
5 4-OH(OA) 100.0±5.5 6.58(6.01-7.19) 5.18 5.01 0.17
6 4-Me 52.0±1.4 77.95(67.32-90.41) 4.11 4.05 0.06
7 2,4-F2 41.7±0.2 263.48(235.45-295.11) 3.58 3.67 -0.09
AIT
8 Synephrine 57.6±5.6 150.03(125.77-179.70) 3.82 3.9 -0.08
9 2-Me,4-Br 41.1±1.1 23.62(20.19-27.83) 4.63 4.59 0.04
10 2,4-Me2 55.0±3.9 13.65(12.80-14.54) 4.86 4.85 0.01
11 2,6-Et2 50.2±2.2 26.13(25.04-27.26) 4.58 4.55 0.03
SBAT
12 3-F 40.8±1.5 35.04(29.43-41.65) 4.46 4.31 0.15
13 3,4-Cl2 52.5±6.2 17.51(14.45-21.29) 4.76 4.73 0.03
14 3,5-Cl2 45.7±4.6 16.25(13.41-19.80) 4.79 5.15 -0.36
AIO
15 2,6-Et2 57.9±1.8 16.84(13.92-20.19) 4.77 4.83 -0.06
16 2-Et,6-iPr 42.5±0.8 13.16(10.39-16.54) 4.88 4.84 0.04
17 CAO 40.0±1.1 5.07(4.12-6.14) 5.29 5.15 0.14
SPIT
18 2,6-Et2 104.0±1.6 8.08(6.32-10.26) 5.09 5.16 -0.07
AII
19 2,6-Me2 47.7±7.6 15.03(11.38-19.92) 4.82 4.88 -0.06
20 2-Me,6-Et 47.6±2.7 9.54(7.48-12.10) 5.02 5.04 -0.02
21 2,6-Et2 104.6±1.4 0.76(0.49-1.13) 6.12 6.12 0
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using same subset of the most active structures (5, 18 and 21). The
rationale underlying this model is that the most active structures
tend to explore the best spatial and electronic interactions with
receptor, while the least active do not and tend to have unfavorable
steric or electronic interactions. Fig. 2 shows octopamine agonist
AII 21 with the highest activity and OA 5 embedded in a receptor
surface model generated from the top 3 molecules. A rigid fit was
performed to superimpose each structure so that it overlays the shape
reference compound AII 21. An ethyl group of 21 is superimposed
with an aminoethanol side chain of 5. The receptor surface model is
colored by H-bond: a purple sign stands for a positive contribution
of H-bond and a light-blue sign stands for a negative contribution
of H-bond. The phenyl ring and 2,6-diethyl substituents have weak
tendency to have an H-bond, while the nitrogen atom of 5 and one
of nitrogen atom of imidazolidine in 21 share an area of strong H-
bond contribution. The nitrogen atom of 5 actually serves as an H-
bond acceptor (Hirashima et al., 2002a). The nitrogen atom of
imidazolidine in 21 has a positive ionizable feature (Hirashima et
al., 2002b), suggesting that it has a tendency to serve as an H-bond
acceptor. The other nitrogen atom of 21 and the p-OH of 5 show a
variable tendency to have an H-bond. Similarly, Fig. 3 shows another
full octopamine agonist, SPIT 18, and octopamine is embedded in a
receptor surface model generated from the top 3 molecules. An ethyl
group of 18 is superimposed on an aminoethanol side chain of 5.
The nitrogen atom of 5 and the sulfur atom of 18 share an area of
strong H-bond contribution. The sulfur of 18 actually serves as an
H-bond acceptor (Hirashima et al., 2002c). The 3-nitrogen atom of
imidazolidine in 18 and p-OH of 5 have a variable tendency to have
an H-bond.
The best model generated using the descriptors from the
closed receptor surface model is given in Equation (1), which was
statistically significant and used to correctly predict the activities of
a set of training molecules ranging over 3 orders of magnitude (max.
pKa 6.12 and min. pKa 2.82), indicating that these models could be
useful tools to design active octopamine agonists. The energies of
interaction between the receptor surface model and each molecular
model were added to the study table as new columns, which were
used for generating QSARs. Instead of one total number which is
the sum of the interactions evaluated between each point on the
surface and each molecular model, leading to one extra column in
the study table, the energies at each surface point are available.
Depending on the size of the drug molecules, this is potentially a
great number of surface points. The number of variables for Equation
(1) was 986. Ten percent of all new significant columns of variables
were automatically used as independent X variables in the generation
of QSAR. In order to quantitatively understand the dependence of
biological activities on receptor surface model parameters of
octopamine agonists, regression analysis was applied to
representative 22 study compounds (Vmax > 40%) listed in Fig. 1a
and Table 1, leading to Equation (1).
pKa = 4.82948 + 2.46196(ELE/567 – 0.137016)2  + 3.92126ELE/
1565 - 1.19472ELE/1670 - 3.59779ELE/2177 + 3.86016ELE/3002
– 7.92195(VDW/678)2 - 0.898844(VDW/1404 + 0.010941) -
3.36632(TOT/678)2  - 1.68885(TOT/1866 + 0.243149) -
4.86016(TOT/2746 + 0.245914) – 2.94225(TOT/2746 + 0.114432)
+ 3.76445(TOT/2755 + 0.283752) + 4.13854(TOT/2755 + 0.267161)
(1)
where n = 22, r2 = 0.971, CV-r2 = 0.720, predicted sum of squares =
2.998 and Bsr2 = 0.968+0.001. The descriptors ELE/567, ELE/1565
Figure 2. The octopamine agonist 21 with the highest activity and OA 5
embedded in an receptor surface model generated from 5, 18 and 21 computed
using the Wyvill steric function colored by H-bond contribution. The purple
sign stands for a positive contribution of H-bond and a light-blue sign stands
for a negative contribution of H-bond.
Figure 3. The octopamine agonist 18 and OA 5 embedded in an receptor
surface model generated from 5, 18 and 21 computed with the Wyvill steric
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etc are the electrostatic interaction energy of the molecule with the
receptor at points 567, 1565 etc. The descriptors VDW/678 and VDW/
1404 are the Van der Waals interaction energy of the molecule with
the receptor at point 678 and 1404 etc. The descriptors TOT/678,
TOT/1866 etc are the added energy of both electrostatic interaction
energy and Van der Waals interaction energy at point 678, 1866 etc.
The term n means the number of data points; r-squared (r2), the
square of the correlation coefficient, which is used to describe the
goodness of fit of the data of the study compounds to the QSAR
model; cross-validated r2 (CV-r2), a squared correlation coefficient
generated during a validation procedure using the equation: CV-r2 =
(SD - predicted sum of squares)/SD; SD, the sum of squared
deviations of the dependent variable values from their mean;
predicted sum of squares, the sum of overall compounds of the
squared differences between the actual and the predicted values for
the dependent variables. The predicted sum of squares value is
computed during a validation procedure for the entire training set.
The larger the predicted sum of squares value, the more reliable is
the equation. A CV-r2 is usually smaller than the overall r2 for a
QSAR equation. It is used as a diagnostic tool to evaluate the
predictive power of an equation generated using the G/PLS method.
Cross-validation is often used to determine how large a model
(number of terms) can be used for a given data set. For instance, the
number of components retained in G/PLS can be selected to be that
which gives the highest CV-r2. Bootstrap r2 (Bsr2) is the average
squared correlation coefficient calculated during the validation
procedure (Cerius2 tutorial, Accelrys Inc., www.accelrys.com/
cerius2). A Bsr2 is computed from the subset of variables used one-
at-a-time for the validation procedure. It can be used more than one
time in computing the r2 statistic.
Table 1 depicts structures of octopamine agonists, their
experimental Ka values, calculated pKa values using Equation (1),
and differences between observed and calculated pKa values. In
case predicted activity is overestimated, deviation is obtained by
calculating predicted activity subtracted by experimental value and
indicated by a minus sign. In case predicted activity is
underestimated, deviation is obtained by calculating experimental
activity subtracted by predicted value. Residuals (observed versus
calculated from Table 1) are plotted in Fig. 4.
Once the desired receptor surface model had been
constructed, all the structures in the test sets were evaluated against
the model. The evaluation consists of computing several energetic
descriptors that are based upon the interactions between ligand and
model. By using receptor data to develop a QSAR model, the
goodness of fit can be evaluated between a candidate structure and
a postulated pseudo-receptor. The predictive character of the QSARs
was further assessed using test molecules, whose Vmax values are
less than 40% and whose structures are shown in Fig. 1b, outside of
the training set. The best statistically significant Equation (1) was
applied to access these octopamine agonists. The predicted values
of these molecules are listed in Table 2. The octopamine agonists
showed reasonable predicted activities according to Equation (1) in
intracellular cAMP production. Residuals (observed versus
calculated from Table 2) are plotted in Fig. 5. These results may
imply that the process of calculating a receptor surface model treats
these structures reasonably, although they have low Vmax values.
Discussion
QSAR modeling is an area of research pioneered by Hansch
and Fujita (1964), Hansch and Leo (1995), and Golender and
Vorpagel (1993). QSAR attempts to model the activity of a series of
compounds using measured or computed properties of the
compounds. Receptor surface models are quantitative and differ from
pharmacophore models, which are qualitative, in that the former
Figure 4. Correlation of observed pKa values with calculated pKa values from
Table 1 using Equation (1) in study set.
Figure 5. Correlation of observed pKa values with calculated pKa values from
Table 2 using Equation (1) in test set.7 Hirashima A, Morimoto M, Kuwano E, Eto M. 2003.  Octopaminergic agonists for the cockroach neuronal octopamine receptor.  9pp.  Journal of Insect
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Table 2. Effect of OA agonists on the adenylate-cyclase activity in homogenates of American cockroach nerve cords in test seta
aSee the text for experimental details.  The adenylate-cyclase activity of P. americana was measured according to Nathanson’s procedure and the cAMP levels
were measured by a RIA.  Basal (control) and OA (100 µM)-stimulated (Vmax) adenylate cyclase activities were 116.2+5.4 and 1,473.3+59.3 pmol cAMP/min/
mg of protein, respectively.  In parentheses, 95% confidence limits are shown.  Ka and 95% confidence limit values were calculated with the Macintosh
personal computer system using a sigmoidal curve-fitting  program designed for log dose-probit activity analyses.
bCalculated by Equation (1).
cIn case predicted activity is overestimated, deviation is obtained by calculating predicted activity subtracted by experimental value and indicated by minus. In
case predicted activity is underestimated, deviation is obtained by calculating experimental activity subtracted by predicted value.
Compound pKa




23 H(D) 34.2±1.1 215.24(187.47-247.95) 3.67 3.34 0.33
24 H(L) 11.1±3.4 262.57(193.61-344.80) 3.58 3.41 0.17
25 3-Br 13.4±0.9 154.00(103.75-232.52) 3.81 3.35 0.46
26 3-Cl 19.0±0.6 157.63(128.21-193.68) 3.8 3.99 -0.19
27 3-NO2 19.2±0.2 407.55(1083.37-1846.91 2.85 3.58 -0.73
28 4-NO2 33.9±0 298.36(280.53-317.65) 3.53 3.65 -0.12
29 4-CF3 31.8±1.5 99.82(87.32-114.29) 4 3.66 0.34
30 4-MeO 8.8±0.5 3.51(2.52-4.88) 5.45 5.85 -0.4
31 4-MeS 25.9±1.5 1033.02(859.05-1247.86 2.91 3.41 -0.5
32 4-Et 25.0±0.9 465.34(387.24-556.93) 3.33 3.36 -0.03
33 2,3-Cl2 15.6±0.9 137.24(82.00-212.16) 3.86 3.3 -0.56
34 2,4-Cl2 31.0±3.6 192.30(165.79-223.06) 3.72 3.85 -0.13
35 2,4-Me2 11.6±0.9 217.75(109.38-449.32) 3.66 3.34 0.32
36 2,5-F2 26.7±1.7 728.79(585.31-921.35) 3.14 3.32 -0.18
37 2,6-(MeO)2 16.6±0.4 555.13(334.87-917.15) 3.26 3.48 -0.22
38 3,5-Cl2 30.0±0.5 121.37(98.43-149.89) 3.92 3.34 0.58
39 IND 13.8±0.8 581.64(358.11-1025.27) 3.24 3.91 -0.67
40 THI 18.5±1.5 1328.80(849.64-2218.85 2.88 3.45 -0.57
41 Tyramine 22.4±5.6 24.88(19.65-31.28) 4.6 4.79 -0.19
AIT
42 2-Br,4-Me 25.0±2.5 148.39 (136.27-161.37) 3.83 2.98 0.85
43 2-Me,4-Cl 36.7±3.8 3.09(2.06-4.82) 5.51 5.62 -0.11
44 MCT6 16.0±0.8 205.01(144.37-280.93) 3.69 3.14 0.55
45 DET5 13.3±1.2 151.32(119.24-191.64) 3.82 3.5 0.32
46 DET6 39.8±3.6 158.92(130.35-193.83) 3.8 3.17 0.63
SBAT
47 H 20.9±1.0 29.51(17.86-56.69) 4.53 3.6 0.93
48 2-Cl 24.3±1.5 192.02(105.91-315.60) 3.72 3.84 -0.12
49 2-F 29.1±0.6 162.88(122.07-230.02) 3.79 3.55 0.24
50 3-CF3 26.1±3.3 69.55(44.89-102.85) 4.16 4.58 -0.42
51 4-MeO 28.5±0.6 4.65(3.06-6.99) 5.33 5.37 -0.04
52 2,4-Cl2 34.3±0.9 27.55(18.99-38.81) 4.56 4.52 0.04
53 2-F,4-Cl 29.2±1.9 22.63(18.86-27.11) 4.65 3.99 0.66
54 2,5-Cl2 27.9±2.2 8.91(5.15-14.35) 5.05 4.37 0.68
55 2,6-(MeO)2 8.1±0.6 59.09(23.25-141.57) 4.23 3.34 0.89
56 3-Cl,4-F 12.3±0.7 10.74(3.93-22.72) 4.97 4.24 0.73
57 3,4-F2 19.3±2.9 80.36(59.83-111.14) 4.09 4.89 -0.8
58 L-APAT 37.3±0.7 609.25(552.91-672.55) 3.22 3.4 -0.18
59 D-APAT 16.0±1.2 328.60(252.17-4321.21) 3.48 3.42 0.06
60 BPAT 22.7±0.6 185.65(27.84-861.26) 3.73 4.44 -0.71
AIO
61 4-I 19.1±2.8 23.13(17.18-31.01) 4.64 5.38 -0.74
62 2-Me,4-Br 33.9±2.3 19.54(16.00-24.38) 4.71 5.04 -0.33
63 2,4-(MeO)2 29.9±2.1 31.24(16.26-56.13) 4.51 3.65 0.86
64 2,6-iPr2 13.9±1.4 152.20(100.57-219.87) 3.82 4.1 -0.28
65 2,3,4,5-Cl4 27.0±2.0 29.68(24.45-36.23) 4.53 3.89 0.64
66 DCAO 28.6±0.7 14.71(11.47-18.77) 4.83 4.65 0.18
SPIT
67 2-Me,4-Cl 30.6±0.4 1.99(1.61-2.47) 5.7 4.96 0.74
68 2,4-Me2 10.5±0.5 34.64(18.50-59.33) 4.46 5.34 -0.88
69 2-Me,5-Cl 10.8±0.7 201.47 (165.13-251.48) 3.7 3.89 -0.19
70 2,6-iPr2 23.8±0.3 59.49(46.85-75.42) 4.23 4.29 -0.068 Hirashima A, Morimoto M, Kuwano E, Eto M. 2003.  Octopaminergic agonists for the cockroach neuronal octopamine receptor.  9pp.  Journal of Insect
Science, 3:10, Available online: insectscience.org/3.10
tries to capture essential information about the receptor, while the
latter only captures information about the commonality of
compounds that bind. Receptor surface models tend to be
geometrically overconstrained (and topologically neutral) since, in
the absence of steric variation in a region, they assume the tightest
steric surface that fits all training compounds. Receptor surface
models do not contain atoms, but try to directly represent the essential
features of an active site by assuming complementarity between the
shape and properties of the receptor site and the set of binding
compounds. The receptor surface model application uses 3D surfaces
that define the shape of the receptor site by enclosing the most active
members (after appropriate alignment) of a series of compounds.
The global minimum of the most active compound 21 in the study
compounds (based on the value in the activity column) was made
as the active conformer. It really is just one of possibly many self-
consistent models that fit the biological-activity data.
Octopamine is not likely to penetrate either the cuticle or
the central nervous system of insects effectively, since it is fully
ionized at physiological pH. Derivatization of the polar groups would
be one possible solution to this problem in trying to develop potential
pest-control agents. Generally speaking, antagonists are hydrophillic
and they are not suitable for insecticides, because they can not
penetrate through insect cuticle. Agonists also show higher binding
affinity for the receptor (pKi: 9.54-3.92, Hirashima et al., 1999c)
than antagonists (pKi: 8.99-4.09, Roeder, 1990). Therefore, it may
be more applicable to develop agonists than antagonists as
insecticides. Actually chlordimeform (pKi: 6.91, Roeder and
Nathanson, 1993), whose active form N-demethylchlordimeform
(pKi: 8.74) shows agonist activity (Nathanson and Hunnicutt, 1981),
and Amitraz (pKi: 7.67) were developed as acaricides. Although
AII 21 showed the highest activity both in octopamine agonist (pKa:
6.12) and binding (pKi: 9.54) activities, it showed no acaricidal
activity, probably because it can not penetrate through insect cuticle,
because SPITs 18 and 67, which contain sulfur atom in the molecule,
had acaricidal activity (Hirashima et al., 1992). Additionally,
chlordimeform and 67 stimulated juvenile-hormone esterase
followed by increase of ecdysteroids leading to delay of pupation
in Tribolium freemani (Hirashima et al., 1998c). Furthermore, the
octopamine agonists reported here inhibited calling behavior
(Hirashima et al., 2003a) and in vitro pheromone synthesis of Plodia
interpunctella (Hirashima et al., 2003b), whose action may be via a
tyramine receptor (unpublished data), suggesting possible cross
reactivity of those compounds with tyramine receptor.
There are several receptors that can be activated by
octopamine in the central nervous system that can either activate or
inhibit adenylyl cyclase activity (Brody and Cravchik, 2000). In
addition, at least one of these receptors may be expressed in up to
six alternatively spliced forms that may have different functional
properties. Maximal stimulation of nerve cord adenylate-cyclase
activity by 18, 21 and 67 was inhibited by several antagonists,
including mianserin, cyproheptadine, chlorpromazine and gramine
(Hirashima et al., 1992). The rank-order ability of these antagonists
to block the maximal adenylate cyclase activation by 18, 21 and 67
was identical to the rank-order ability of the same antagonists to
block the enzyme activation by an optimally effective concentration
of octopamine. The β-adrenergic antagonist propranolol was less
potent in this respect. Thus, the action of these octopamine agonists
is same as that of octopamine, due to cAMP elevation at OAR2.
The above receptor surface model studies show that full agonists
with 2,6-diethyl substituents can be potential ligands to octopamine
receptors. Phenyl ring-substitution requirements for partial
octopamine agonists differ substantially from each other and other
various types of octopamine agonists could be potent, although the
type of compounds tested here are too limited to draw any
conclusions. These derivatives could provide useful information in
the characterization and differentiation of the octopaminergic
receptor. They may help to point the way towards developing
extremely potent, and relatively specific, octopamine ligands, leading
to potential insecticides, although further research on the comparison
of the 3D QSAR from agonists is necessary. In order to optimize
the activities of these compounds as octopamine ligands, more
detailed experiments are in progress.
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